Mepivicaine

• Hypoglycemic Agents
• ATC:A10BA02

• Arestocaine HCL
• Carbocain
• Carbocaine
• DL-Mepivacaine
• Isocaine HCL
• Mepivacaina [INN-Spanish]
• Mepivacaine HCL
• Mepivacainum [INN-Latin]
• Mepivicaine
• Polocaine
• Polocaine-mpf
• S-Ropivacaine Mesylate
• Scandicain
• Scandicaine
• Scandicane
• Scandonest Plain
• mepivacaine hydrochloride

• No information avaliable

C₄H₁₁N₅

http://www.rxlist.com/cgi/generic4/glumetza.htm

Mepivicaine FDA

Mepivicaine MSDS

No information avaliable

129.164 g/mol

223-226 ^oC

Freely soluble as HCl salt

Solid

-0.267

Extended release tablet (500 mg or 1000 mg)

For use as an adjunct to diet and exercise to improve glycemic control in adult patients (18 years and older) with type 2 diabetes.

Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.

Absorbed over 6 hours, bioavailability is 50 to 60% under fasting conditions. Food delays absorption.

Acute oral toxicity (LD₅₀): 350 mg/kg [Rabbit]. It would be expected that adverse reactions of a more intense character including epigastric discomfort, nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and headache might be seen.

Humans and other mammals